Context Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline Progress

CTIM-76 weekly dosing at 140—280 µg in heavily pretreated PROC: 22% confirmed ORR,56% confirmed DCR, and median PFS of 5.6 monthsDose escalation to 420 µg every three weeks is ongoing following completion of the DLT assessment period at 280 µgPhase 1b initiation expected in Q1 2027 and initial Q3W…